Over the last 5 years the Duke Comprehensive Cancer Center has undergone substantial growth and renewal. A new Director and Deputy Director have been appointed. The Cancer Center membership has been mobilized. A strategic plan is being developed to facilitate communication, collaboration and interaction among Cancer Center members and to enhance educational, community and patient care activities. Some 201 members from 12 Departments participate in 11 Programs and utilize 16 Shared Resources. The Molecular Biology Shared Resource has been significantly strengthened, computer facilities have been updated, the Isolation Facility has been doubled in size and new resources have been created for biofermentation, irradiation, production of transgenic mice, conjugation of radionuclides, NMR spectroscopy, generation of LAK cells, measurement of hematopoietic colonies and autologous bone marrow transplantation. Organizationally, a matrix design has been converted into a matrix-plus. A Section of Cell Growth Regulation has been created, permitting the primary recruitment of 14-16 new investigators whose work is directly relevant to tumor biology. The Medical Center has committed a quasi-endowment and 34,500 new sf of research space to back this recruitment. During the. current grant period clinical programs in surgical and pediatric oncology have continued to mature and new leaders have been recruited in medical oncology, radiation oncology, gynecologic oncology and biostatistics. Support is requested for Staff, Programs, Shared Resources and Development to implement fully the strategic plan for the Duke Comprehensive Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-17
Application #
3101402
Study Section
Special Emphasis Panel (SRC (A2))
Project Start
1976-09-01
Project End
1993-12-31
Budget Start
1990-01-01
Budget End
1990-12-31
Support Year
17
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955
Powell Gray, Bethany; Kelly, Linsley; Ahrens, Douglas P et al. (2018) Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 115:4761-4766
Abdi, Khadar; Lai, Chun-Hsiang; Paez-Gonzalez, Patricia et al. (2018) Uncovering inherent cellular plasticity of multiciliated ependyma leading to ventricular wall transformation and hydrocephalus. Nat Commun 9:1655
Hudson, Kathryn E; Rizzieri, David; Thomas, Samantha M et al. (2018) Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. Br J Haematol :

Showing the most recent 10 out of 513 publications